1. Introduction {#sec1-marinedrugs-17-00204}
===============

Cardiovascular disease (CVD) is the main cause of death in Europe \[[@B1-marinedrugs-17-00204]\], and among CVD, hypertension has become a problem of global, epidemic proportions \[[@B2-marinedrugs-17-00204]\]. Long-term hypertension results in increased risk of stroke, heart attack, arterial aneurysm and kidney failure \[[@B3-marinedrugs-17-00204],[@B4-marinedrugs-17-00204]\]; even moderate hypertension can shorten the life span \[[@B3-marinedrugs-17-00204]\]. Hypertension is a global problem that influences the health of the population and also exerts a substantial influence on the economy. The direct medical costs associated with CVD in the United States in 2010 were valued at approximately 273 billion USD and this figure is estimated to reach 818 billion USD by 2030 \[[@B5-marinedrugs-17-00204]\].

The inhibition of enzymes such as renin (EC 3.4.23.15) and angiotensin-I-converting enzyme (ACE-I, EC 3.4.15.1) is known to be effective at lowering blood pressure \[[@B6-marinedrugs-17-00204]\]. These enzymes operate within a number of metabolic pathways including the renin‒angiotensin‒aldosterone system (RAAS), the renin‒chymase system (RCS), the kinin‒nitric oxide system (KNOS) and the neutral endopeptidase system (NEPS) \[[@B7-marinedrugs-17-00204]\]. Synthetic drugs that target renin and ACE-I are available for the clinical treatment of hypertension. These drugs include captopril, enalapril and lisinopril. Despite the efficiency of these drugs, adverse side effects including dry cough, taste disturbances, skin rashes, renal failure, congenital malformations and angioneurotic oedema have been reported \[[@B8-marinedrugs-17-00204],[@B9-marinedrugs-17-00204]\]. Thus, it is necessary to find safer enzyme inhibitors for the prevention and remedy of hypertension from natural products \[[@B10-marinedrugs-17-00204]\].

Bioactive peptides or cryptides are sequences of between 2 and 30 amino acids. These peptides show no activity within the parent protein, but after their release by different methods, i.e., enzymatic hydrolysis or fermentation, they may show beneficial biological activities. Thus, bioactive peptides obtained from different food protein sources are considered a promising alternative to synthetic drugs \[[@B2-marinedrugs-17-00204]\] and these food-based strategies to control high blood pressure can be considered an excellent intervention to improve health and wellness and decrease health care costs \[[@B3-marinedrugs-17-00204]\]. Numerous renin and ACE-I-inhibitory peptides have been obtained previously by hydrolysis of animal proteins from milk \[[@B11-marinedrugs-17-00204]\], eggs \[[@B12-marinedrugs-17-00204]\] and blood \[[@B6-marinedrugs-17-00204],[@B13-marinedrugs-17-00204]\]. Several peptides were also identified from the macroalga *Palmaria palmata* \[[@B14-marinedrugs-17-00204]\] and indeed terrestrial crops \[[@B15-marinedrugs-17-00204],[@B16-marinedrugs-17-00204]\].

Macroalgae are a rich source of multiple biologically active compounds including polysaccharides and proteins \[[@B17-marinedrugs-17-00204],[@B18-marinedrugs-17-00204]\]. Chlorophyta (green) and Rhodophyta (red) macroalgae are the most promising algae to be exploited as sources of protein for functional food and feed development \[[@B17-marinedrugs-17-00204],[@B19-marinedrugs-17-00204]\]. Amongst the green macroalgae, *Ulva* sp. is a promising biomass as it has a worldwide distribution \[[@B20-marinedrugs-17-00204]\] and levels of protein documented in the literature of between 7% and 33% of the dry weight of the algal plant \[[@B21-marinedrugs-17-00204],[@B22-marinedrugs-17-00204]\]. Apart from its total protein content, marine organisms have adapted to extreme environmental conditions including high salt concentration and pressure conditions and the composition and primary sequences of amino acids of these marine proteins are different from those of land proteins \[[@B10-marinedrugs-17-00204]\]. Thus, marine macroalgae are interesting protein resources for the generation of novel antihypertensive (renin and ACE-I inhibitory) peptides by enzymatic hydrolysis \[[@B10-marinedrugs-17-00204]\].

The aim of this study was to generate and characterise novel bioactive protein hydrolysates from *U. lactuca* as this macroalgae is considered a relatively untapped source of biologically active molecules. The protein extracted from *Ulva* sp. was hydrolysed using the food-grade enzyme papain; enriched using 1, 3 and 10 kDa molecular weight cutoff (MWCO) filtration membranes; and further purified using preparative RP-HPLC. The antihypertensive activities of the fractions was measured in vitro for renin and ACE-I inhibition and active fractions subsequently characterised using mass spectrometry (LC/MS/MS). The amino acid sequence of peptides contained in these fractions was determined and they were subsequently assessed for their bitterness, resistance to gastrointestinal digestion, potential toxicity and estimated allergenicity using multiple in silico predictive tools.

2. Results and Discussion {#sec2-marinedrugs-17-00204}
=========================

The methodological approaches used in this study to generate and identify bioactive peptides from *Ulva* sp. are schematically represented in [Figure 1](#marinedrugs-17-00204-f001){ref-type="fig"} and further described in [Section 3](#sec3-marinedrugs-17-00204){ref-type="sec"}.

2.1. Protein Extraction {#sec2dot1-marinedrugs-17-00204}
-----------------------

The extracts generated from *Ulva* sp. had a protein content of 69.19 ± 1.44%, as assessed by the BCA method. Previous studies extracting protein from macroalgae *Himanthalia elongata* using a sonication water bath also reported similar protein contents (63.38 ± 0.49%) in the algal extracts \[[@B23-marinedrugs-17-00204]\]. Moreover, the yields of total protein extracted from *Ulva* sp. were 4649.98 ± 96.68 mg of protein per 100 g of dried biomass.

2.2. Generation of Hydrolysates and Antihypertensive Activities In Vitro {#sec2dot2-marinedrugs-17-00204}
------------------------------------------------------------------------

A papain hydrolysate of the crude *Ulva* protein was generated in order to release biologically active peptides or cryptides from the parent proteins. Previous reports emphasised the need to generate and use protein hydrolysates as the presence of intact or partially hydrolysed proteins can induce immune-mediated allergic reactions in sensitive individuals \[[@B24-marinedrugs-17-00204]\]. Although the need for amino acids could also be supplied by mixtures of synthetic amino acids, the generation of protein hydrolysates remains the most promising source of peptides \[[@B24-marinedrugs-17-00204]\]. The protein hydrolysates can be produced at a large scale industrially, and the peptides generated have good absorption and stability when compared to free amino acids, particularly glutamine, tyrosine and cysteine \[[@B24-marinedrugs-17-00204]\].

To concentrate and purify the different peptides generated during the enzymatic hydrolysis, the full hydrolysate was filtered through MWCO filtration units of 1, 3, and 10 kDa separately, generating three additional ultra-filtered fractions, namely 1 kDa-UFH, 3 kDa-UFH and 10 kDa-UFH. The control of the molecular size of the peptides generated after a protein hydrolysis is an essential step in the development of dietary products \[[@B24-marinedrugs-17-00204]\]. MWCO filtration has been proven to be the most efficient post-hydrolysis procedure to separate non-hydrolysed proteins, high MW peptides or residues of the proteolytic enzymes added to perform the hydrolysis \[[@B24-marinedrugs-17-00204]\].

The in vitro renin and ACE-I inhibitory activities of crude protein, full hydrolysate (FH) and the three ultra-filtered fractions (1 kDa-UFH, 3 kDa-UFH and 10 kDa-UFH) are shown in [Figure 2](#marinedrugs-17-00204-f002){ref-type="fig"}. When assayed for renin inhibition, the crude protein did not inhibit renin and the full hydrolysate inhibited renin by 3.70 ± 1.39% compared to the specific renin inhibitor, Z-Arg-Arg-Pro-Phe-His-Sta-Ile-His-Lys-(Boc)-OMe, which was used as the positive control. Ultrafiltration enhanced renin inhibitory activity and the different fractions inhibited renin as follows: 3 kDa by 20.79 ± 0.15%; 10 kDa-UFH by 21.19 ± 0.27% and 1 kDa-UFH by 6.89 ± 0.18%. The renin inhibitory activities were all less than 20% and compared negatively to previously identified renin inhibitors such as hydrolysates from the macroalga *Palmaria palmata* \[[@B14-marinedrugs-17-00204]\] or other terrestrial crops such as *Avena sativa* \[[@B25-marinedrugs-17-00204]\].

In the case of ACE-I, crude *Ulva* sp. protein inhibited ACE-I by 79.87 ± 0.18% at a concentration of 1 mg/mL and after hydrolysis with papain the ACE-I inhibition activity of the FH was increased to 82.37 ± 0.05% when assayed at 1 mg/mL concentrations compared to the initial protein. Following ultrafiltration, ACE-I inhibition also increased, with the maximum inhibitory activity observed for the 1 kDa-UFH (93.03 ± 0.87%) followed by both the 3 kDa-UFH (86.64 ± 2.17%) and 10 kDa-UFH (88.12 ± 0.02%) when all fractions were assayed at a concentration of 1 mg/mL. These results are in agreement with previous reports that describe the structure of peptides with ACE-I inhibitory activities as short amino acid sequences, including di and tri-peptides \[[@B26-marinedrugs-17-00204]\] or even up to 10 amino acid residues \[[@B27-marinedrugs-17-00204]\]. The low concentration of small peptides in the FH compared to the ultra-filtered fractions and the blocking effect of large peptides on the antihypertensive activity of small peptides, could explain these results. Moreover, the ACE-I inhibitory activities of all the fractions, particularly the 1 kDa-UFH, were higher than other promising peptide fractions obtained from terrestrial plants and animal proteins. Gangopadhyay, Wynne, O'Connor, Gallagher, Brunton, Rai and Hayes \[[@B15-marinedrugs-17-00204]\] generated protein hydrolysates from barley (*Hordeum vulgare*) and purified the hydrolysate using membranes, being the most promising fractions the 3 kDa fraction that inhibited ACE-I by 70.37 ± 0.67%, followed by the 10 kDa UFH (57.42 ± 4.68%) and the full hydrolysate (47.23 ± 2.62%). Similarly to our results, Lafarga, Rai, O'connor and Hayes \[[@B6-marinedrugs-17-00204]\] generated hydrolysates from bovine haemoglobin proteins and the highest ACE-I inhibition was appreciated in the peptides contained in the 1 kDa fraction that showed approximately 40% of ACE-I inhibition, compared to the 3 and 10 kDa samples.

2.3. Purification by Preparative Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) and Antihypertensive Activity In Vitro {#sec2dot3-marinedrugs-17-00204}
---------------------------------------------------------------------------------------------------------------------------------------

To further purify the most promising peptides contained in the 1 kDa-UFH fraction, preparative RP-HPLC was performed, the peptides were collected every minute and the separation was monitored at 214 nm, wavelength of absorbance of peptide bonds, and 280 nm, which is the wavelength of choice to detect residues of aromatic amino acids \[[@B28-marinedrugs-17-00204]\]. The RP-HPLC chromatogram obtained for the 1 kDa-UFH fraction of *Ulva* sp. is presented in [Figure 3](#marinedrugs-17-00204-f003){ref-type="fig"}. The chromatogram at 214 nm shows main absorbance peaks for peptide bonds at minutes 9‒11, 21‒30, 41‒44 and a final plateau at 52‒62 min. However, when monitoring the absorbance at 280 nm, the main peaks related to the presence of aromatic amino acids were mainly appreciated at minutes 41‒44 and the previously observed plateau at minutes 52‒62 decreased significantly. The presence of branched amino acids at the N-terminal position and aromatic amino acid residues at the C-terminal position in peptides has been described as one key structural feature governing the ACE-I inhibitory activity of peptides \[[@B29-marinedrugs-17-00204]\]. Thus, peptides containing amino acids such as leucine, valine, alanine and the aromatic amino acids tyrosine, phenylalanine or tryptophan are likely to inhibit ACE by competing for binding to the catalytic sites of the enzyme \[[@B30-marinedrugs-17-00204],[@B31-marinedrugs-17-00204]\]. From the chromatogram shown in [Figure 3](#marinedrugs-17-00204-f003){ref-type="fig"}, using RP-HPLC monitored at 280 nm, the fractions collected at minutes 41‒44 were likely to content high amounts of aromatic amino acids and, thus, have a strong potential to inhibit ACE-I. When the peptide fractions 41‒44 were assayed at 1 mg/mL for ACE-I inhibition, the antihypertensive activity of all these fractions was statistically higher compared to the previously assayed 1 kDa-UFH. The average ACE-I of all the fractions was in all cases higher than 95%, close to the levels of inhibition of ACE-I of the captopril used as a positive control. The peptides contained in these four peptide fractions (Fr41‒44) were identified by HPLC-MS/MS.

2.4. Identification of Peptides Using HPLC-MS/MS and Bitterness Estimation {#sec2dot4-marinedrugs-17-00204}
--------------------------------------------------------------------------

A total of 48 peptides were identified from the four selected fractions (Fr41‒44) of 1 kDa-UFH showing potent ACE-I inhibitory activities. The amino sequences of these novel peptides and their modifications were further characterized by the observed and calculated molecular masses, theoretical and observed mass/charge (*m*/*z*), and charge (z) as it is shown in [Table 1](#marinedrugs-17-00204-t001){ref-type="table"}. The total ion chromatogram after the HPLC separation in mass spectrometry is also presented in [Figure 4](#marinedrugs-17-00204-f004){ref-type="fig"}. The amino acid sequences had green algae origin and were compared to previously reported peptides in the BIOPEP database \[[@B32-marinedrugs-17-00204]\]. All the peptides identified were novel and not previously reported in this database. As these peptides are intended for oral intake, one factor that could influence consumption when incorporated into a food product could be the taste \[[@B24-marinedrugs-17-00204]\]. The process of protein hydrolysis generates short peptides that are normally bitter and not accepted by Western consumers, regardless of the potential health benefits of the products \[[@B33-marinedrugs-17-00204]\]. The Q-values were calculated for the identified peptides based on the method of Ney \[[@B34-marinedrugs-17-00204]\], who estimates the bitterness of the peptides on the basis of the solubility data of each individual amino acid. When a peptide has a molecular weight (MW) lower than 6 kDa and the Q-value of the peptide exceeds 1400 cal/mol, the sequence is predicted to be bitter. The peptides identified in Fr41‒44 have generally Q-values below the threshold of bitterness (see [Table 1](#marinedrugs-17-00204-t001){ref-type="table"}). Only the sequences SAGVLPWK, GAAPTPPSPPPATKPSTPPKPPT, IECCLLFALV, PVGCLPK, DAVEIWRVK, DEVIPGAL, PKPPALCN and PPNPPNPPN with Q-values ranging from 1440 to 1743.33 cal/mol could be predicted to be bitter. Although this estimation method can be applied to the majority of the known peptides, a few authors have also suggested that the bitterness of the peptides could be related to the MW of the amino acid sequences rather than the Q-value \[[@B35-marinedrugs-17-00204]\].

2.5. In Silico Analyses {#sec2dot5-marinedrugs-17-00204}
-----------------------

### 2.5.1. In Silico GI Enzymatic Digestion {#sec2dot5dot1-marinedrugs-17-00204}

Several issues that will influence the future applicability and usage of bioactive peptides include the water solubility of the molecules, the stability of the products and the bioavailability of the peptides when passing through biological barriers such as the GI tract \[[@B6-marinedrugs-17-00204]\]. The resistance of peptides to the enzymatic degradation in the GI tract will determine the bioavailability of the initial peptides. Moreover, novel amino acid sequences could be released from the parent peptide during the process of digestion and may exert toxic, allergenic or other potent biological activities when absorbed. After the in silico enzymatic simulations performed, only a few peptides remained intact, namely ATKPAN, SGAASASGAA (from Fr41), AGGPNQPPN, AANITVPAAN (identified in Fr42), EAEPAEAA, GAAPTPPSPPPATKPSTPPKPPT (obtained in Fr43) and PPNPPNPPN (Fr44). All the peptides obtained from the in silico enzymatic simulation were further compared with the BIOPEP database \[[@B32-marinedrugs-17-00204]\] to identify previously reported bioactive peptides. There were 16 di- and tri-peptides released after the GI enzymatic simulation previously reported as bioactives (see [Table 2](#marinedrugs-17-00204-t002){ref-type="table"}).

The main biological activities described for these amino acid sequences are antihypertensive (ACE-I inhibitors) and anti-diabetic (dipeptidyl peptidase IV inhibitors) peptides. Furthermore, the sequence GGV was described as an inhibitor of the enzyme 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase) and could have a hypocholesterolemic effect \[[@B36-marinedrugs-17-00204]\].

### 2.5.2. In Silico Prediction of Allergenicity and Bioactivity {#sec2dot5dot2-marinedrugs-17-00204}

Food allergy is a huge concern in the development of nutraceuticals and the formulation of novel and safe food products \[[@B42-marinedrugs-17-00204]\]. Allergic reactions start when immunoglobulin E binds and activates mast and basophil cells upon the contact with food allergens. These activated cells release granules containing inflammatory mediators and other molecules, generating an immediate allergic reaction that could be life-threatening \[[@B43-marinedrugs-17-00204]\]. Immunoglobulin E-mediated food allergies affect between 3% and 8% of children and 1--3% of adults in developed countries and their prevalence and severity are increasing. The most commonly described sources of food allergens are milk, eggs and wheat, which produce reactions that are normally overcome with age as the patients acquire tolerance. However, peanuts, tree nuts and fish allergies often persist over a lifetime \[[@B43-marinedrugs-17-00204]\]. The potential allergenicity of proteins from macroalgae has not yet been fully explored. Recently, Polikovsky, Fernand, Sack, Frey, Müller and Golberg \[[@B42-marinedrugs-17-00204]\] reported the first study on the existence of potential allergens in proteins extracted from *Ulva* sp. The authors suggested that the potential allergenicity of *Ulva* sp. proteins will depend on the extraction conditions as the protocols of extraction will influence the mass transfer of molecules from the macroalgal biomass to the extract. Moreover, the European Food Safety Authority (EFSA) favours the use of in silico tools to predict the potential allergenicity of food proteins \[[@B44-marinedrugs-17-00204]\].

In the current study, the 70 novel peptides released after the in silico GI enzymatic digestion were further analysed for their potential allergenicity in silico using AllerTop version 2.0 (<http://www.ddg-pharmfac.net/AllerTOP>). This in silico prediction tool is based on the transformation of amino acid descriptors of the protein strings into uniform vectors, followed by using the k nearest neighbours algorithm (kNN, *k* = 1) to classify the peptides based on a set containing 2427 known allergens and 2427 non-allergens \[[@B45-marinedrugs-17-00204]\]. The amino acid sequences that could be described as probably allergenic are summarised in [Table 3](#marinedrugs-17-00204-t003){ref-type="table"}, together with their nearest allergenic protein, while the probably non-allergenic 42 peptides are summarised in [Table 4](#marinedrugs-17-00204-t004){ref-type="table"}.

This information will be useful to prevent allergic systemic reactions produced when the allergens cross the intestinal mucosa and enter the circulation, creating a reaction that may compromise the circulatory and nervous systems \[[@B43-marinedrugs-17-00204]\]. The European Food Safety Authority (EFSA) favours the use of in silico tools to predict the initial potential allergenicity of food proteins \[[@B44-marinedrugs-17-00204]\]. The results on the allergenicity of these peptides suggest that papain hydrolysates from *Ulva* sp. could result in potentially allergenic peptides after GI digestion and, thus, this parameter should be further assessed in vitro and in vivo to comply with the current food allergen labelling European regulations such as the Regulation (EU) No.1169/2011.

The potential of the allergenic and non-allergenic peptides to be bioactive is also summarised in [Table 3](#marinedrugs-17-00204-t003){ref-type="table"} and [Table 4](#marinedrugs-17-00204-t004){ref-type="table"}, as analysed using PeptideRanker. Several peptides scored high in peptide ranker (\>0.6); in particular, peptides GPPPPSP and GTF, with scores over 0.8, show potential for further in vivo evaluation as some of the peptides assayed in vitro did not perform as well as expected using in vivo models \[[@B46-marinedrugs-17-00204]\].

### 2.5.3. In Silico Prediction of Toxicity {#sec2dot5dot3-marinedrugs-17-00204}

The protein hydrolysates of this study were generated from edible parts of *Ulva* sp. destined for human consumption and the enzyme papain is a food-grade molecule obtained from plant (*Carica papaya*). Moreover, protein hydrolysates generated using similar enzymatic procedures from animal \[[@B6-marinedrugs-17-00204],[@B13-marinedrugs-17-00204]\] and other edible protein sources such as plants \[[@B15-marinedrugs-17-00204]\] and algae \[[@B14-marinedrugs-17-00204]\] have not been reported to pose a serious health risk to consumers. None of the identified peptides in this study were predicted to be toxic using ToxinPred (<http://crdd.osdd.net/raghava/toxinpred/>) as seen in the negative SVM scored summarised in [Table 3](#marinedrugs-17-00204-t003){ref-type="table"} and [Table 4](#marinedrugs-17-00204-t004){ref-type="table"}. The toxicity assessments should be further explored using cell lines and animal studies before the product is made available for human consumption. However, protein hydrolysates and low MW peptides are generally considered non-toxic \[[@B6-marinedrugs-17-00204]\] and are less allergenic than full or partially hydrolysed proteins \[[@B24-marinedrugs-17-00204]\]. Protein hydrolysates have been used to develop hypoallergenic infant formulas \[[@B47-marinedrugs-17-00204]\], but also in specific diets to treat patients with metabolic disorders affecting amino acid digestion, absorption and metabolism \[[@B24-marinedrugs-17-00204]\]. Other uses of protein hydrolysates include the treatment of malnutrition associated with age \[[@B48-marinedrugs-17-00204]\] or other diseases such as cancer, trauma, burns and hepatic encephalopathies, mainly due to the easy absorption of short peptides \[[@B24-marinedrugs-17-00204]\].

3. Material and Methods {#sec3-marinedrugs-17-00204}
=======================

3.1. Biological Materials {#sec3dot1-marinedrugs-17-00204}
-------------------------

The macroalgae *Ulva lactuca* was kindly supplied by Portomuiños (Galicia, Spain). Macroalgae were collected at Muxía (A Coruña, Galicia, Spain) on 10 June 2013. Following harvest, the seaweeds were cleaned and epitopes removed, oven-dried, milled and vacuum preserved until further analysis.

3.2. Chemicals {#sec3dot2-marinedrugs-17-00204}
--------------

Ammonium sulphate, formic acid (FA), trifluoroacetic acid (TFA), acetonitrile (ACN), HPLC-grade water CHROMASOLV^®^, dimethyl sulfoxide (DMSO), papain (EC 3.4.22.2) from *Carica papaya* ≥3 U/mg, QuantiPro BCA assay kit and the inhibitors of ACE-I (Captopril©) and renin (Z-Arg-Arg-Pro-Phe-His-Sta-Ile-His-Lys-(Boc)-OMe) were all supplied by Sigma-Aldrich (Dublin, Ireland). The ACE-I and renin inhibitory screening assay kits were supplied by Dojindo Laboratories (Kumamoto, Japan) and Cayman Chemical Company (Ann Arbor, MI, USA), respectively. All the other chemicals used were of analytical grade.

3.3. Protein Extraction and Quantification {#sec3dot3-marinedrugs-17-00204}
------------------------------------------

Crude protein was extracted following the method previously described by Garcia-Vaquero, Lopez-Alonso and Hayes \[[@B23-marinedrugs-17-00204]\]. Briefly, 10 g of dried seaweed were suspended in 1 L of ultrapure water and ultra-sonicated for 1 h (Branson 3510EMT, Branson Ultrasonics Corporation, Danbury, CT, USA) and left overnight on a magnetic stirrer plate (IKA RCT basic safety control) at 4 °C. The solution was then centrifuged at 10,000× *g* for 1 h and the supernatant decanted. The pellet fraction was re-suspended in 0.5 L of ultrapure water and subjected to a second extraction procedure as described above. Supernatants from both days were pooled together; the solution was then saturated to 80% with ammonium sulphate for 1 h at 4 °C and centrifuged at 20,000× *g* for 1 h to precipitate the protein. The protein precipitates were subsequently dialyzed using Thermo Scientific™ SnakeSkin™ dialysis tubing, 3.5 kDa MWCO (Thermo Fisher Scientific, Hudson, NH, USA) against ultrapure water at 4 °C. Dialyzed protein extracts were freeze-dried and stored at ‒20 °C until further analysis.

The protein contents in the crude extracts of *Ulva lactuca* were determined using the QuantiPro BCA Assay Kit (Sigma-Aldrich, Saint Louis, MO, USA). Samples were prepared according to the manufacturer's instructions using Greiner 96-well flat-bottom plates (Sigma) and absorbance values were read at 562 nm in a microplate reader (FLUOstar Omega, BMG Labtech, Offenburg, Germany).

3.4. Protein Hydrolysis and Molecular Weight Cutoff Filtration {#sec3dot4-marinedrugs-17-00204}
--------------------------------------------------------------

*Ulva* sp. hydrolysates of the crude protein extracts were prepared using a 1 L bioreactor with temperature and pH control (Bioflo 110, New Brunswick Scientific Co Inc., Edison, NJ, USA). The crude protein was dispersed in ultrapure water at a concentration of 0.01 g/mL at a total volume of 0.5 L. The hydrolysis was carried out by the addition of 1% papain^®^. Conditions used included stirring at 300 rpm, pH 6 and temperature maintained at 60 °C for a 24 h period. The hydrolysis was stopped by heating the mixture to 95 °C for 10 min in a water bath. The full hydrolysate (FH) was further concentrated using 10 kDa, 3 kDa and 1 kDa MWCO membranes obtaining three fractions, namely 1 kDa-UFH, 3 kDa-UFH and 10 kDa-UFH, respectively. All the hydrolysates were freeze dried, vacuum-packed and stored at ‒20 °C until further use.

3.5. Preparative Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) {#sec3dot5-marinedrugs-17-00204}
--------------------------------------------------------------------------------

The 1 KDa-UFH was further purified by preparative RP-HPLC (Varian Pro-Star, Agilent Technologies, USA) using a Luna^®^ C18 (Phenomenex^®^, 5 µm 100 μm × 21.2 mm). Prior to analysis, samples were re-dissolved (5% *w*/*v*) in HPLC-grade water with 0.1% TFA and filtered through 0.2 μm filters (Agilent Captiva, Agilent Technologies, Santa Clara, CA, USA). The column was equilibrated with HPLC-grade water with 0.1% TFA at a flow rate of 1 mL/min for 10 min. Following the injection (1 mL) the sample was separated using a linear gradient of ACN (2--98% *v*/*v*, 90 min) containing 0.1% TFA at a flow rate of 1 mL/min. The absorbance was monitored at wavelengths 214 and 280 nm and the eluted fractions were collected every minute. The solvents contained in the fractions (ACN and TFA) were vapored under nitrogen and the peptide fractions were freeze-dried.

3.6. In Vitro Antihypertensive Activities {#sec3dot6-marinedrugs-17-00204}
-----------------------------------------

### 3.6.1. ACE-I Inhibition Assay {#sec3dot6dot1-marinedrugs-17-00204}

The ACE-I inhibitory activity of the samples was measured according to a method based on the detection of the amount of 3-hydroxybutyrate (3-HB) generated from 3-hydroxybutyryl-Gly-Gly-Gly (3HB-GGG). The measurement was done using the materials enclosed in an ACE-I inhibition kit-WST (Dojindo Laboratories) and prepared according to the manufacturer's instructions. All fractions were assayed at a concentration of 1 mg/mL in HPLC-grade water in triplicate and standard deviations of the mean (SEM) were calculated. Briefly, the enzyme working solution was prepared by dissolving enzyme B in 2 mL of HPLC-grade water and adding 1.5 mL of this solution to enzyme A. The indicator working solution was prepared by dissolving enzyme C and coenzyme with 3 mL of HPLC-grade water each and adding 2.8 mL of each of them to the indicator solution to prepare the indicator working solution. Negative control or blank 1 was prepared by adding 20 μL of HPLC-grade water and 20 μL of substrate buffer. Reagent blank 2 wells were prepared by adding 40 μL of HPLC-grade water and 20 μL of substrate buffer. Inhibitor wells were prepared by adding 20 μL of the unknown sample and 20 μL of substrate buffer. The ACE-I inhibitor captopril© was used as a positive control at the same concentration and following the same procedure as the samples in the inhibitor wells. The enzymatic reaction was started by adding 20 μL of enzyme working solution to each inhibitor and negative control wells. The plate was covered and incubated at 37 °C. After 1 h, 200 μL of indicator working solution was added to each well and the microwell plate was further incubated at room temperature for 10 min. The absorbance of the reaction was measured with a microplate reader (FLUOstar Omega, BMG Labtech, Offenburg, Germany) at 450 nm. The ACE-I inhibition percentage for each sample was calculated using Equation (1):

### 3.6.2. Renin Inhibition Assay {#sec3dot6dot2-marinedrugs-17-00204}

The renin inhibition assay was performed using an enzymatic kit (Cayman Chemical Company) and following the manufacturer's recommendations. *Ulva* sp. proteins, hydrolysates and the positive control (Z-Arg-Arg-Pro-Phe-His-Sta-Ile-His-Lys-(Boc)-OMe) were dissolved in DMSO at a concentration of 1 mg/mL. The assay started by transferring 10 μL of samples and control to a microplate, followed by the addition of 20 μL renin substrate, 150 μL assay buffer and 10 μL renin. The plates were incubated at 37 °C for 15 min and the fluorescence of the reaction was read at excitation wavelengths of 340 nm and emission wavelengths of 500 nm in a microplate reader (FLUOstar Omega, BMG Labtech, Offenburg, Germany). The percentage of renin inhibition was calculated using Equation (2):

3.7. Identification of Peptides by Mass Spectrometry {#sec3dot7-marinedrugs-17-00204}
----------------------------------------------------

ACE-I inhibitory and renin inhibitory fractions were characterised using liquid chromatography and tandem mass spectrometry (LC-MS/MS). The samples were re-suspended in 50 μL in 2% ACN containing 0.1% TFA and 5 µL were injected into a Nano-LC Ultra 1D Plus system (Eksigent AB Sciex, Dublin, CA, USA) and pre-concentrated using a trap column (C18-CL Eksigent AB Sciex, 3 µm, 350 μm × 0.5 mm) for 5 min using 0.1% TFA at a flow rate of 3 µL/min. The samples were loaded onto an analytical column (C18-CL Nikkyo, 3 µm, 75 μm × 12 cm) equilibrated in 0.1% FA in water. Elution was carried out using a linear gradient from 5% to 35% of solvent B in A for 45 min (solvent A: 0.1% FA in water; solvent B: ACN containing 0.1% FA) at a flow rate of 0.3 μL/min. The peptides were analysed using nanoESI qQTOF (nanoelectrospray ionization in a quadrupole/time-of-flight TripleTOF 5600+ system from AB Sciex Instruments (Framingham, MA, USA)). The sample was ionised by applying 2.8 kV to the spray emitter and the analyses were carried out in a data-dependent mode. MS1 scans were acquired from 350 to 1250 *m*/*z* for 250 ms, the quadrupole resolution was set to 'UNIT' for MS2 experiments and the scans were acquired from 100 to 1500 *m*/*z* for 50 ms in 'high sensitivity' mode. The switch criteria used were charge (1+ to 5+), minimum intensity and 70 counts per second (cps). Up to 25 ions were selected for fragmentation after each survey scan and the dynamic exclusion was set to 15 s.

The data from LC-MS/MS were further processed using ProteinPilot version 5.0 search engine (AB Sciex, Framingham, MA, USA) using the default parameters to generate the peak list directly from the 5600 TripleTOF 5600+ files. The Paragon algorithm (Shilov et al. \[[@B49-marinedrugs-17-00204]\]) of ProteinPilot version 5.0 was used to search in Uniprot and NCBI_GreenAlgae databases, selecting no enzyme specificity, no taxonomy restriction and with the search effort of the software set to "Thorough".

3.8. In Silico Analyses {#sec3dot8-marinedrugs-17-00204}
-----------------------

The bitterness of the characterised peptides was estimated by the "Q rule" proposed by Ney \[[@B34-marinedrugs-17-00204]\]. This estimation method is based on the calculation of a Q-value for each peptide on the basis of its amino acid composition and the solubility data of each of the individual amino acids of the peptide sequences.

Furthermore, characterised peptides from *Ulva* sp. were assessed for potential cleavage by GI tract enzymes including pepsin pH 1.3 and pH \> 2.0 (EC 3.4.23.1), trypsin (EC 3.4.21.4) and chymotrypsin (EC 3.4.21.1) using the ExPASy PeptideCutter tool (<http://web.expasy.org/peptide_cutter/>). The novel peptide sequences generated after the GI in silico digestion were also compared against the BIOPEP database (<http://www.uwm.edu.pl/biochemia/index.php/pl/biopep>) to identify the previously reported active sequences \[[@B32-marinedrugs-17-00204]\]. The allergenicity of the novel sequences after the GI in silico digestion was predicted using AllerTOP version 2.0 (<http://www.ddg-pharmfac.net/AllerTOP/index.html>). The toxicity of all the peptides was scored in ToxinPred (<http://crdd.osdd.net/raghava/toxinpred/>) using a virtual scanning method (VSM) Swiss-Prot based and a SVM threshold of 0.0 \[[@B50-marinedrugs-17-00204]\]. The potential biological activity of all the peptides was predicted using the scores calculated in PeptideRanker (<http://distilldeep.ucd.ie/PeptideRanker/>) \[[@B51-marinedrugs-17-00204]\].

3.9. Statistical Analyses {#sec3dot9-marinedrugs-17-00204}
-------------------------

All the statistical analyses were performed using SPSS version 24.0. The biological activities in vitro of the different protein, hydrolysate and fractions were analysed using a univariate general linear model and LSD post hoc tests. In all the cases the criterion for statistical significance was *P* \< 0.05.

4. Conclusions {#sec4-marinedrugs-17-00204}
==============

This study shows the great potential of *Ulva* sp. protein hydrolysates generated using the food-grade enzyme papain as a source of bioactive peptides. The hydrolysates and fractions generated had low renin and high ACE-I inhibitory activities in vitro. The peptides of the most active hydrolysates were fully identified and in silico tools including ExPASy PeptideCutter, ToxinPred and AllerTOP were used to predict the resistance of the peptides to gastrointestinal enzymatic digestion, toxicity and allergenicity of the peptides, respectively. Using this mixed in vitro‒in silico approach, 48 novel peptides were identified and 86 novel amino acid sequences were generated after the in silico gastrointestinal simulation. Although the peptides were predicted to be non-toxic, several sequences were predicted to be probably allergenic. Further in vivo studies will be needed to confirm the antihypertensive activity of the hydrolysate and the safety of the identified bioactive peptides.
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![Schematic representation of the procedures used to generate and identify bioactive peptides from *Ulva lactuca* using in vitro and in silico tools.](marinedrugs-17-00204-g001){#marinedrugs-17-00204-f001}

![In vitro renin and angiotensin-I-converting enzyme (ACE-I) inhibitory activities of crude protein, full hydrolysate (FH) and ultra-filtered hydrolysates (1, 3 and 10 kDa-UFH) generated from *Ulva* sp. The samples and positive controls (the renin inhibitor Z-Arg-Arg-Pro-Phe-His-Sta-Ile-His-Lys-(Boc)-OMe and the ACE-I inhibitor captopril) were assayed at 1 mg/mL. The results are expressed as mean ± standard deviation of the mean (SEM). The different letters in the figure indicate statistical significant differences (*P* \< 0.05) between the different samples tested.](marinedrugs-17-00204-g002){#marinedrugs-17-00204-f002}

![Preparative reversed-phase HPLC (RP-HPLC) chromatogram obtained from the 1 kDa-UFH monitored at wavelengths 214 and 280 nm. The ACE-I inhibitory activities of captopril, 1 kDa-UFH and the samples from RP-HPLC collected at minutes 41‒44 (Fr41‒Fr44) are also presented at the end of the figure. The results are expressed as mean ± standard deviation of the mean (SEM). The different letters in the figure indicate statistical significant differences (*P* \< 0.05) between the samples tested.](marinedrugs-17-00204-g003){#marinedrugs-17-00204-f003}

![Total ion chromatogram (TIC) separation of the selected HPLC fractions for mass spectrometry analysis. (**A**) corresponds to Fr41, (**B**) to Fr42, (**C**) to Fr43 and (**D**) to Fr44.](marinedrugs-17-00204-g004){#marinedrugs-17-00204-f004}

marinedrugs-17-00204-t001_Table 1

###### 

Peptides identified by HPLC-MS/MS from Fr41‒44 collected by RP-HPLC of *Ulva* sp. protein hydrolysates with papain. The Q-values are an estimation of the bitterness of the peptides and are calculated and summarised in the last column.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Samples                   Amino Acid Sequences   Modifications   Observed\   Calculated\   Observed\   Theoretical\   Charge\   Database                           Accessions                   Q-Values
                                                                   MW          MW            *m*/*z*     *m*/*z*        (+)                                                                       
  ------------------------- ---------------------- --------------- ----------- ------------- ----------- -------------- --------- ---------------------------------- ---------------------------- ----------
  **Fr41**                  TGGSLHAA                               712.41      712.35        357.21      357.18         2         NCBInr                             XP_005851095.1; EFN58993.1   607.5

  VVPKAAPPPN                                       988.76          988.57      495.39        495.29      2              NCBInr    XP_005843189.1; EFN51087.1         1343                         

  ATKPAN                                           600.41          600.32      301.21        301.17      2              NCBInr    XP_001696486.1; XP_001696477.1     1001.67                      

  SGAASASGAA                                       748.40          748.34      375.21        375.17      2              NCBInr    RRRRRKXZ51346.1                    377                          

  HSAVFAAS                                         788.51          788.38      395.26        395.20      2              NCBInr    GAX77766.1                         883.75                       

  NGNAASPGQPPLEVH                                  1486.84         1486.72     744.43        744.37      2              NCBInr    RRRRRJAC80986.1                    960                          

  HQWGGAPQH                                        1016.69         1016.46     509.35        509.24      2              NCBInr    XP_002500034.1; ACO61292.1         794.44                       

  KFKGMNHINDIEKFK                                  1847.96         1847.97     616.99        617.00      3              UniProt   sp\|B9DRW5                         1304                         

  GAVHAMVDTAKIHKGKK                                1789.95         1790.00     597.66        597.67      3              UniProt   RRRRRsp\|Q3TC72                    1048.23                      

  **Fr42**                  AGGPNQPPN                              850.48      850.39        426.25      426.20         2         NCBInr                             XP_001694488.1; EDP02483.1   941.11

  AANITVPAAN                                       940.58          940.50      471.30        471.26      2              NCBInr    XP_002957564.1; EFJ41334.1         1062                         

  DSLSAIGGAPDG                                     1058.45         1058.49     530.23        530.25      2              NCBInr    JAC65094.1                         885.83                       

  SAGVLPWK                                         856.50          856.48      429.26        429.25      2              NCBInr    KXZ46138.1                         1500                         

  DGLIDGL                                          694.35          701.36      695.36        702.37      1              UniProt   tr\|A0A1C9C803\|A0A1C9C803_9FLOR   1270                         

  GDLIDVA                                          694.35          701.36      695.36        702.37      1              UniProt   tr\|M1VAH3\|M1VAH3_CYAM1           1270                         

  NQVTNLIVA                                        970.46          970.54      486.24        486.28      2              UniProt   tr\|A0A1G4NVL3\|A0A1G4NVL3_9FLOR   1091.11                      

  GSASGAFVY                                        857.46          857.39      429.74        429.70      2              UniProt   tr\|M1V5F7\|M1V5F7_CYAM1           972.22                       

  **Fr43**                  HGPPPPSPYRSAAGRAAL                     1800.90     1800.94       601.31      601.32         3         NCBInr                             XP_005846003.1; EFN53901.1   1297.22

  EAEPAEAA                                         786.37          786.34      394.19        394.18      2              NCBInr    XP_005852249.1; EFN60147.1         898.75                       

  SIAGVAAFIG                                       904.48          904.50      453.25        453.26      2              NCBInr    JAC64130.1                         1251                         

  YAAKMRK                                          866.54          866.48      434.28        434.25      2              NCBInr    XP_007512502.1; CCO17102.1         1337.14                      

  DDLKGTF                                          794.38          794.38      398.20        398.20      2              NCBInr    XP_003058074.1; EEH58025.1         1155.71                      

  GGVYGTSAR                                        866.50          866.42      434.26        434.22      2              NCBInr    XP_001700029.1; EDP07725.1         722.22                       

  GSECMWFAS                                        1016.33         1016.37     509.17        509.19      2              NCBInr    XP_001693035.1; EDP03604.1         923.33                       

  AGFSYFGESS                                       1050.45         1050.43     526.23        526.22      2              NCBInr    XP_002951597.1; EFJ47408.1         957                          

  DLLALRELDVACN                                    1443.77         1443.74     722.89        722.88      2              NCBInr    JAT73014.1                         1167.69                      

  NGGDLPGAL                                        812.42          812.40      407.22        407.21      2              NCBInr    XP_003055625.1; EEH60877.1         968.89                       

  ALLQQQAQMAAALPLPP                                1759.90         1759.97     587.64        587.66      3              NCBInr    XP_005847720.1; EFN55618.1         1299.41                      

  LTPCAVPE                                         828.43          828.41      415.22        415.21      2              NCBInr    KXZ44026.1                         1383.75                      

  ERTGRVAM                                         918.48          918.47      460.25        460.24      2              NCBInr    KXZ43890.1                         771.25                       

  LNCALK                                           660.43          660.36      331.22        331.19      2              NCBInr    XP_001416982.1; ABO95275.1         1176.67                      

  GAAPTPPSPPPATKPSTPPKPPT                          2190.15         2190.17     731.06        731.06      3              NCBInr    XP_002958348.1; EFJ40570.1         1558.69                      

  IECCLLFALV                                       1122.55         1122.58     562.28        562.30      2              NCBInr    GAX82307.1                         1585                         

  PVGCLPK                                          712.40          712.39      357.21        357.20      2              NCBInr    JAC75907.1                         1550                         

  DEDESSFGK                                        1012.47         1012.40     507.24        507.21      2              UniProt   tr\|R7QMS5\|R7QMS5_CHOCR           712.22                       

  GASPVTFVFT                                       1024.49         1024.52     513.25        513.27      2              UniProt   tr\|M1VHB3\|M1VHB3_CYAM1           1295                         

  AGDLGAYG                                         722.39          722.32      362.20        362.17      2              UniProt   tr\|A0A1X6NU59\|A0A1X6NU59_PORUM   911.25                       

  RSARVRVGSTAT                                     1259.69         1259.71     630.85        630.86      2              UniProt   tr\|A0A1X6NKL7\|A0A1X6NKL7_PORUM   665.83                       

  INNNKIITNL                Deamidated (N)\@2      1156.65         1156.65     579.33        579.33      2              UniProt   tr\|A0A1Z1MP80\|A0A1Z1MP80_9FLOR   1323                         

  DAVEIWRVK                                        1114.58         1114.61     558.30        558.31      2              UniProt   tr\|R7QMS0\|R7QMS0_CHOCR           1488.89                      

  **Fr44**                  DEVIPGAL                               812.43      812.43        407.22      407.22         2         NCBInr                             GAX84002.1                   1440

  DATFCGDLDDA                                      1141.54         1141.42     571.78        571.72      2              NCBInr    XP_001697003.1; EDP00695.1         830                          

  PKPPALCN                                         838.47          838.44      420.24        420.23      2              NCBInr    KXZ44308.1                         1562.5                       

  PPNPPNPPN                                        942.56          942.46      472.29        472.24      2              NCBInr    XP_002955492.1; EFJ43345.1         1743.33                      

  TPALVSQLH                                        964.50          964.53      483.26        483.27      2              NCBInr    XP_011396301.1; KFM23431.1         1195.56                      

  TMSDRFL                                          868.51          868.41      435.26        435.21      2              NCBInr    XP_002499460.1; ACO60718.1         1160                         

  AAGAAPLL                                         682.44          682.40      342.23        342.21      2              NCBInr    AAW51128.1                         1297.5                       

  LIKELDSN                                         930.62          930.50      466.32        466.26      2              UniProt   tr\|A0A1Z1MG56\|A0A1Z1MG56_9FLOR   1303.75                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Bioactive peptides generated after the in silico gastrointestinal digestion of the identified peptide from *UIva* sp. already available in the scientific literature. The data were attained from the BIOPEP database (<http://www.uwm.edu.pl/biochemia/index.php/pl/biopep>) on 14 February 2019.

  Amino Acid Sequences   Bioactivity In Vitro *\**                           Reference
  ---------------------- --------------------------------------------------- --------------------------------------------------------------------------------
  AA                     ACE-I inhibitor                                     Cushman et al. \[[@B37-marinedrugs-17-00204]\]
  AG                     ACE-I inhibitor                                     Cheung, Wang, Ondetti, Sabo and Cushman \[[@B29-marinedrugs-17-00204]\]
  AS                     DPP IV inhibitor                                    Lan et al. \[[@B38-marinedrugs-17-00204]\]
  DG                     ACE-I inhibitor                                     Meisel, Walsh, Murray and Fitzgerald \[[@B7-marinedrugs-17-00204]\]
  GA                     ACE-I inhibitor                                     Cheung, Wang, Ondetti, Sabo and Cushman \[[@B29-marinedrugs-17-00204]\]
  GD                     ACE-I inhibitor                                     Cheung, Wang, Ondetti, Sabo and Cushman \[[@B29-marinedrugs-17-00204]\]
  GGV                    HMG-CoA reductase inhibitor                         Soares, Mendonça, de Castro, Menezes and Arêas \[[@B36-marinedrugs-17-00204]\]
  GK                     ACE-I inhibitor                                     Cheung, Wang, Ondetti, Sabo and Cushman \[[@B29-marinedrugs-17-00204]\]
  GM                     ACE-I inhibitor                                     Cheung, Wang, Ondetti, Sabo and Cushman \[[@B29-marinedrugs-17-00204]\]
  IG                     ACE-I inhibitor                                     Cheung, Wang, Ondetti, Sabo and Cushman \[[@B29-marinedrugs-17-00204]\]
  IH                     DPP IV inhibitor                                    Lan, Ito, Ohno, Motoyama, Ito and Kawarasaki \[[@B38-marinedrugs-17-00204]\]
  NH                     DPP IV inhibitor                                    Lan, Ito, Ohno, Motoyama, Ito and Kawarasaki \[[@B38-marinedrugs-17-00204]\]
  PK                     DPP IV inhibitor                                    Lan, Ito, Ohno, Motoyama, Ito and Kawarasaki \[[@B38-marinedrugs-17-00204]\]
  TM                     DPP IV inhibitor                                    Lan, Ito, Ohno, Motoyama, Ito and Kawarasaki \[[@B38-marinedrugs-17-00204]\]
  VK                     DPP IV inhibitor                                    Lan, Ito, Ohno, Motoyama, Ito and Kawarasaki \[[@B38-marinedrugs-17-00204]\]
  ACE-I inhibitor        Wang and De Mejia \[[@B39-marinedrugs-17-00204]\]   
  VR                     DPP IV inhibitor                                    Nongonierma and FitzGerald \[[@B40-marinedrugs-17-00204]\]
  ACE-I inhibitor        Gómez-Ruiz et al. \[[@B41-marinedrugs-17-00204]\]   

\* Abbreviations in the table correspond to: angiotensin-I-converting enzyme (ACE-I), dipeptidyl peptidase IV inhibitor (DPP IV inhibitor), 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (HMG-CoA reductase inhibitor).
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###### 

Peptides identified as having the potential to cause allergy obtained after in silico gastrointestinal digestion and assessment using online tools ToxinPred and Peptideranker. The toxicological, bioactivity scores and the nearest protein identified in different databases are also summarised for each peptide.

  ----------------------------------------------------------------------------------------------------------------
  Amino Acid Sequence   MW\        SVM Scores ^a^   PeptideRanker Scores ^b^   Nearest Protein
                        (Da)                                                   
  --------------------- ---------- ---------------- -------------------------- -----------------------------------
  AANITVPAAN            940.4978   −1.3             0.144457                   NCBI GI number 2154734

  AAPPPN                565.627    −0.46            0.792864                   NCBI GI number 33323477

  AGD                   261.235    −0.8             0.283992                   UniProtKB accession number O01949

  AGGPNQPPN             850.3933   −0.72            0.621643                   NCBI GI number 33323477

  CGD                   293.295    −0.79            0.646691                   NCBI GI number 102834

  DD                    248.192    −0.79            0.098852                   UniProtKB accession number Q17282

  DDA                   319.271    −0.8             0.127455                   UniProtKB accession number O01949

  DEVIPGA               699.759    −0.45            0.185675                   NCBI GI number 543491

  EVH                   383.404    −0.82            0.0380427                  NCBI GI number 21465915

  GASPVT                530.579    −0.97            0.247962                   NCBI GI number 2500822

  GESS                  378.339    −0.76            0.0716116                  NCBI GI number 32363197

  GGAPQH                565.586    −0.86            0.388533                   UniProtKB accession number P86254

  GSASGA                448.433    −0.93            0.250858                   NCBI GI number 543482

  GSECM                 525.592    −0.42            0.554283                   NCBI GI number 162927

  IDVA                  416.475    −0.84            0.0871288                  NCBI GI number 539716

  IECC                  466.568    −0.25            0.448357                   NCBI GI number 14285595

  IITN                  459.543    −0.84            0.106012                   UniProtKB accession number Q93YG7

  IK                    259.349    −0.8             0.0974139                  NCBI GI number 157829757

  INNNK                 601.66     −0.81            0.0938778                  NCBI GI number 1083651

  NGNAASPGQPPL          1122.203   −0.78            0.505873                   NCBI GI number 33323477

  NQVTN                 574.591    −1.01            0.0559664                  UniProtKB accession number P00709

  SAIGGAPDG             743.771    −0.67            0.397354                   NCBI GI number 285005077

  SAR                   332.36     −0.81            0.278711                   NCBI GI number 81890324

  TGR                   332.36     −0.8             0.276659                   UniProtKB accession number Q7M1M4

  TPAL                  400.475    −0.8             0.342157                   NCBI GI number 18203509

  VAM                   319.419    −0.8             0.264259                   NCBI GI number 9072

  VSQ                   332.357    −0.83            0.0492778                  NCBI GI number 2147092

  VVPK                  441.571    −0.88            0.0810705                  NCBI GI number 2133755
  ----------------------------------------------------------------------------------------------------------------

^a^ SVM scores obtained from in silico analyses using ToxinPred (<http://crdd.osdd.net/raghava/toxinpred/>). Data retrieved on 15 February 2019. ^b^ Biological activity scores obtained from in silico analyses using Peptideranker (<http://distilldeep.ucd.ie/PeptideRanker/>). Data retrieved on 14 February 2019.
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###### 

Probably non-allergenic peptides obtained after in silico gastrointestinal digestion. The toxicological, bioactivity scores and the nearest protein identified in different databases are also summarised for each peptide.

  --------------------------------------------------------------------------------------------------------
  Amino Acid Sequence       MW\          SVM\         PeptideRanker\   Nearest Protein
                            (Da)         Scores ^a^   Scores ^b^       
  ------------------------- ------------ ------------ ---------------- -----------------------------------
  AAAL                      344.411      −0.84        0.28869          UniProtKB accession number A9UGV6

  AAGAAP                    456.499      −1.01        0.352249         UniProtKB accession number Q7M1V0

  AAK                       288.347      −0.77        0.113614         UniProtKB accession number P27807

  AAL                       273.332      −0.84        0.310569         UniProtKB accession number A9UGV6

  AAS                       247.251      −0.82        0.123531         UniProtKB accession number A2WQG7

  AM                        220.287      −0.8         0.74549          UniProtKB accession number Q8IWT0

  ATKPAN                    600.32312    −0.88        0.129647         UniProtKB accession number Q8WYQ3

  CN                        235.258      −0.8         0.63423          UniProtKB accession number P01052

  DAT                       305.288      −0.81        0.0954274        UniProtKB accession number Q9NNX6

  DAVEI                     545.59       −0.93        0.0603561        UniProtKB accession number Q9T2R4

  DEDESS                    680.58       −0.78        0.0365686        UniProtKB accession number Q9S8K0

  DS                        220.182      −0.8         0.0878061        UniProtKB accession number O75366

  DSN                       334.286      −0.78        0.104772         UniProtKB accession number P31358

  DVACN                     520.558      −0.68        0.203726         UniProtKB accession number Q7M2H1

  EAEPAEAA                  394.193      −0.99        0.0830328        UniProtKB accession number Q9S8F6

  ER                        303.318      −0.8         0.0704548        UniProtKB accession number Q9T2R8

  GAAPTPPSPPPATKPSTPPKPPT   731.0588     −0.69        0.378489         UniProtKB accession number Q9S8M0

  GAVH                      382.42       −0.77        0.173142         UniProtKB accession number Q9S8I6

  GPPPPSP                   647.729      −0.11        0.870562         UniProtKB accession number Q7M1V1

  GTF                       323.349      −0.8         0.84905          UniProtKB accession number P04234

  GTSAR                     490.517      −0.89        0.151592         UniProtKB accession number Q7M282

  IDG                       303.315      −0.78        0.288785         UniProtKB accession number P86001

  INDIEK                    730.816      −0.97        0.0849714        UniProtKB accession number P86006

  IVA                       301.386      −0.79        0.0757333        UniProtKB accession number Q9S8N5

  NCA                       306.337      −0.77        0.425512         UniProtKB accession number A6N1B4

  NGGDL                     474.471      −0.76        0.567577         UniProtKB accession number P55857

  PGA                       243.263      −0.81        0.674335         UniProtKB accession number Q9S906

  PKPPAL                    621.778      −0.7         0.715386         UniProtKB accession number Q7M1U2

  PLPP                      422.525      −1.04        0.876691         UniProtKB accession number Q7M1V1

  PPNPPNPPN                 942.455933   −0.4         0.855282         UniProtKB accession number Q9S8M0

  PVGCL                     487.615      −0.63        0.734232         UniProtKB accession number P83184

  QQQAQM                    732.809      −0.92        0.216075         UniProtKB accession number Q9UL45

  SAAGR                     460.49       −0.85        0.341095         UniProtKB accession number P80825

  SAGVL                     445.516      −0.99        0.38464          UniProtKB accession number A9UGV7

  SAV                       275.305      −0.82        0.0814653        UniProtKB accession number Q09Y74

  SDR                       376.37       −0.83        0.242439         UniProtKB accession number Q9BXJ1

  SGAASASGAA                748.335144   −1.17        0.2792           UniProtKB accession number Q7M1V0

  SIAGVAA                   587.674      −1.28        0.134975         UniProtKB accession number A9UGV6

  TGGS                      320.302      −0.77        0.17105          UniProtKB accession number Q15517

  TPCAVPE                   715.819      −0.88        0.224438         UniProtKB accession number Q9T2Q0

  VDTAK                     532.594      −0.34        0.0513549        UniProtKB accession number Q9T2R4

  VGSTAT                    534.567      −1.03        0.0691571        UniProtKB accession number Q10ST8
  --------------------------------------------------------------------------------------------------------

^a^ SVM scores obtained from in silico analyses using ToxinPred (<http://crdd.osdd.net/raghava/toxinpred/>). Data retrieved on 15 February 2019. ^b^ Biological activity scores from in silico analyses using Peptideranker (<http://distilldeep.ucd.ie/PeptideRanker/>). Data retrieved on 14 February 2019.
